Profile: Codexis Inc (CDXS.C)
10 Jan 2017
Codexis, Inc., incorporated on January 31, 2002, is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's technologies enable scale-up and implementation of biocatalytic solutions for process development, from research to manufacturing. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company have commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. Its pharmaceutical customers, including several of the global pharmaceutical companies, use its technology, products and services in their manufacturing processes and process development.
The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. It markets and sells enzymes, development services, and Codex Biocatalyst Kits and Panels screening tools, which enable manufacturing processes for APIs and their precursor pharmaceutical intermediates. It also markets and sells pharmaceutical intermediates that are manufactured using its custom enzymes. The Company sells its products and services to both the generic and pharmaceutical end markets. Its products and services have been adopted at various points of the pharmaceutical product lifecycle, from early-stage clinical testing to post-launch commercialization. The Company sells its products primarily to pharmaceutical manufacturers through its directed sales and business development force in the United States and Europe. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
The Company sells Codex Biocatalyst Panels and Kits to customers who are engaged in both drug development and drug manufacturing to allow them to screen and identify possible enzymes that can be applied in the manufacturing processes for their drug candidates and marketed products. Codex Biocatalyst Panels are the tools that provide genetically diverse variants of its enzymes, which allow its customers to determine whether an enzyme produces a desired activity that is applicable to a particular process. Codex Biocatalyst Kits provide subsets of the Codex Biocatalyst Panel enzymes in individual vials for the same purpose. For compounds that are in development, Codex Biocatalyst Panels and Kits, allow innovators to screen and identify possible enzymatic manufacturing processes rapidly and inexpensively for many of their drug candidates in-house, without the risks of disclosing the composition of their molecules before they have received patent protection. Codex Biocatalyst Panels and Kits also generate data that the Company can use to optimize enzymes rapidly for a particular reaction, if necessary, reducing the time required to generate a manufacturing process capable of supporting clinical trials with produced pure drugs.
The Company offers enzyme screening services and enzyme optimization services. The Company uses its software tools, ProSAR and MOSAIC to analyze protein sequence-activity relationships. Its ProSAR and MOSAIC bioinformatics software relates the screening results to the mutations and ranks the individual mutations (ProSAR) and interacting mutations (MOSAIC) with regard to their degree of benefit or detriment, relative to the process parameters tested. Multiplexed gene SOEing is its methodology for rapidly generating gene variants. Using multiplexed gene SOEing, it can test many mutations and combinations thereof in parallel, and because the mutation incorporation is controlled and predetermined before screening, as opposed to random incorporation and selection after screening, the resulting data set can be more optimal for ProSAR analysis.
The Company competes with Merck, GSK, Pfizer, Bristol Myers Squibb, Teva, Solvias AG, Takasago International Corporation, Novozymes, Cambrex Corporation, Almac Group Ltd, BRAIN AG, c-LEcta GmbH, evocatal GmbH, Dupont-Genencor, DSM and A.B. Enterprises.
200 Penobscot Dr
REDWOOD CITY CA 94063-4718